SG10201902407PA - Injectable microparticles for hyper-localized release of therapeutic agents - Google Patents

Injectable microparticles for hyper-localized release of therapeutic agents

Info

Publication number
SG10201902407PA
SG10201902407PA SG10201902407PA SG10201902407PA SG10201902407PA SG 10201902407P A SG10201902407P A SG 10201902407PA SG 10201902407P A SG10201902407P A SG 10201902407PA SG 10201902407P A SG10201902407P A SG 10201902407PA SG 10201902407P A SG10201902407P A SG 10201902407PA
Authority
SG
Singapore
Prior art keywords
hyper
therapeutic agents
localized release
injectable microparticles
microparticles
Prior art date
Application number
SG10201902407PA
Inventor
James A Helliwell
Amanda M Malone
Original Assignee
Eupraxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals Inc filed Critical Eupraxia Pharmaceuticals Inc
Publication of SG10201902407PA publication Critical patent/SG10201902407PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Described herein are injectable drug-loaded microparticles, pharmaceutical composition thereof and methods for using the same in a body compartment or for systemic administration. FIG. 47
SG10201902407PA 2014-09-19 2015-09-18 Injectable microparticles for hyper-localized release of therapeutic agents SG10201902407PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462052959P 2014-09-19 2014-09-19

Publications (1)

Publication Number Publication Date
SG10201902407PA true SG10201902407PA (en) 2019-04-29

Family

ID=55533935

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201701870PA SG11201701870PA (en) 2014-09-19 2015-09-18 Injectable microparticles for hyper-localized release of therapeutic agents
SG10201902407PA SG10201902407PA (en) 2014-09-19 2015-09-18 Injectable microparticles for hyper-localized release of therapeutic agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201701870PA SG11201701870PA (en) 2014-09-19 2015-09-18 Injectable microparticles for hyper-localized release of therapeutic agents

Country Status (14)

Country Link
US (1) US20170246117A1 (en)
EP (1) EP3193847A4 (en)
JP (1) JP2017528527A (en)
KR (1) KR20170056573A (en)
CN (1) CN107106506A (en)
AU (1) AU2015317339A1 (en)
BR (1) BR112017005666A2 (en)
CA (1) CA2960860A1 (en)
CL (1) CL2017000664A1 (en)
IL (1) IL251216A0 (en)
MX (1) MX2017003638A (en)
RU (1) RU2017113354A (en)
SG (2) SG11201701870PA (en)
WO (1) WO2016044799A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CA3003159A1 (en) 2015-10-27 2017-05-04 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
WO2019071243A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for controlled release of therapeutic agents
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC Implantable device for sustained release of a macromolecular drug compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
JP2006523613A (en) * 2002-12-20 2006-10-19 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ Coated particles for sustained release pharmaceutical administration
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US8110284B2 (en) * 2003-07-31 2012-02-07 Sol-Gel Technologies Ltd. Microcapsules loaded with active ingredients and a method for their preparation
BRPI0813274A2 (en) * 2007-06-25 2014-12-30 Otsuka Pharma Co Ltd MICROSPHERES HAVING CORE / COATING STRUCTURE
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
CN102070895B (en) * 2010-11-17 2013-03-27 无锡中科光远生物材料有限公司 Core-shell microcapsule and preparation method thereof
JP6083936B2 (en) * 2011-03-11 2017-02-22 大阪ガスケミカル株式会社 Method for producing sustained release particles
AU2012324013A1 (en) * 2011-11-03 2013-05-23 Gtx, Inc. Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof
EP2819741B1 (en) * 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
CA2907765C (en) * 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Also Published As

Publication number Publication date
KR20170056573A (en) 2017-05-23
JP2017528527A (en) 2017-09-28
CA2960860A1 (en) 2016-03-24
MX2017003638A (en) 2017-11-08
CL2017000664A1 (en) 2018-03-02
RU2017113354A (en) 2018-10-19
IL251216A0 (en) 2017-05-29
AU2015317339A1 (en) 2017-04-27
RU2017113354A3 (en) 2019-04-18
BR112017005666A2 (en) 2017-12-19
WO2016044799A1 (en) 2016-03-24
EP3193847A1 (en) 2017-07-26
US20170246117A1 (en) 2017-08-31
CN107106506A (en) 2017-08-29
SG11201701870PA (en) 2017-04-27
EP3193847A4 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
IL294146A (en) Anti-cmet antibody drug conjugates and methods for their use
HK1248548A1 (en) Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2018002723A (en) Peptidomimetic macrocycles and uses thereof.
MY187540A (en) Compounds active towards bromodomains
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2017091749A8 (en) Shape changing drug delivery devices and methods
PH12016501841A1 (en) Immunosuppressant formulation
EP3512554A4 (en) Platelet compositions and methods for the delivery of therapeutic agents
EP3229824A4 (en) Oral octreotide administered in combination with other therapeutic agents
EP3537997A4 (en) System and method for delivering therapeutic agents to the uterine cavity
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2017000141A (en) Targeted therapeutic nanoparticles and methods of making and using same.
IL275380A (en) Surfactant peptide nanostructures and uses in drug delivery
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
IL265677A (en) Ophthalmic drug sustained release formulation and uses thereof
MX2020007293A (en) Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation.
MX2016011706A (en) Progesterone formulations.
PH12017501979A1 (en) Pharmaceutical compound
PL3630188T3 (en) A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis